Seegene Introduces Groundbreaking Unattended PCR Automation, Transforming Diagnostics at ADLM 2025
Seegene Inc., a renowned leader in molecular diagnostics, made headlines with the announcement of their revolutionary PCR testing system, CURECA™, at the ADLM 2025 conference, the largest diagnostics event in the world, held in Chicago from July 28 to 31. This innovative system is the first in the world to fully automate every aspect of the PCR process, which traditionally required significant human intervention. With capabilities ranging from sample storage to nucleic acid extraction and amplification, CURECA™ promises to redefine the standards of accuracy and efficiency in medical diagnostics.
The design of CURECA™ centers on continuous 24/7 operation, effectively minimizing human errors that are common in laboratory environments. This is particularly significant in reducing variability in test results, a challenge that has historically plagued PCR diagnostics, especially when dealing with diverse sample types such as blood, urine, and stool. The system's advanced pre-treatment module stands out as a critical innovation, automating one of the most labor-intensive and error-prone steps of the PCR process.
Traditionally, pre-treatment has been a bottleneck in laboratory workflows, demanding extensive manual labor, particularly with samples like stool that present unique challenges due to their viscosity. Laboratory personnel often spend long hours on repetitive tasks which can lead to inconsistencies in results. By automating this step, CURECA™ alleviates the labor burden on technicians and ensures a much more reliable output. This shift not only boosts operational efficiency but also allows lab staff to engage in more meaningful work, focusing on data analysis and clinical interpretation rather than mundane tasks.
In addition to its focus on PCR, the prep module of CURECA™ offers versatility in supporting pre-treatment processes for other diagnostic areas, including clinical chemistry and immunoassays, marking a significant leap in diagnostic automation. Its modular design means it can be tailored to suit various laboratory needs, allowing for flexible configurations depending on the size and layout of a laboratory.
Alongside CURECA™, Seegene also introduced STAgora™, a real-time analytics platform designed to enhance clinical decision-making. STAgora™ integrates PCR diagnostic data from hospitals globally, offering insights into regional infection trends and hospital-level results. With over 40 statistical tools available, this platform allows healthcare providers to compare individual test results with regional epidemiological data, facilitating better-informed treatment strategies. The comprehensive analysis provided by STAgora™ is critical for speeding up diagnoses and improving patient care.
Seegene's commitment to expanding access to both CURECA™ and STAgora™ is evident as the company aims to establish pilot partnerships with selected institutions by the end of the year. Early engagement was already seen at the ESCMID Global 2025 conference, signaling strong anticipation for these innovations.
According to Daniel Shin, Executive Vice President and Chief of Global Sales & Marketing at Seegene, "CURECA™ and STAgora™ are not just instruments or software; they signify a new benchmark that will reshape the landscape of diagnostics in clinical settings worldwide." Seegene's dedication to the development of diagnostic technologies spans more than 20 years, during which it has established its presence through significant contributions, such as providing over 340 million COVID-19 tests globally during the pandemic. This experience underscores the company’s capacity for innovation in the rapidly evolving field of molecular diagnostics.
While currently in a pre-commercialization stage, the technologies showcased at ADLM 2025 reflect the high potential for transforming workflows in clinical laboratories. CURECA™ and STAgora™ represent promising advancements that stand to improve diagnostics by reducing human error, enhancing efficiency, and better leveraging workforce capabilities. As Seegene prepares for broader commercialization, it is clear that the future of diagnostics is set for transformative change.
The design of CURECA™ centers on continuous 24/7 operation, effectively minimizing human errors that are common in laboratory environments. This is particularly significant in reducing variability in test results, a challenge that has historically plagued PCR diagnostics, especially when dealing with diverse sample types such as blood, urine, and stool. The system's advanced pre-treatment module stands out as a critical innovation, automating one of the most labor-intensive and error-prone steps of the PCR process.
Traditionally, pre-treatment has been a bottleneck in laboratory workflows, demanding extensive manual labor, particularly with samples like stool that present unique challenges due to their viscosity. Laboratory personnel often spend long hours on repetitive tasks which can lead to inconsistencies in results. By automating this step, CURECA™ alleviates the labor burden on technicians and ensures a much more reliable output. This shift not only boosts operational efficiency but also allows lab staff to engage in more meaningful work, focusing on data analysis and clinical interpretation rather than mundane tasks.
In addition to its focus on PCR, the prep module of CURECA™ offers versatility in supporting pre-treatment processes for other diagnostic areas, including clinical chemistry and immunoassays, marking a significant leap in diagnostic automation. Its modular design means it can be tailored to suit various laboratory needs, allowing for flexible configurations depending on the size and layout of a laboratory.
Alongside CURECA™, Seegene also introduced STAgora™, a real-time analytics platform designed to enhance clinical decision-making. STAgora™ integrates PCR diagnostic data from hospitals globally, offering insights into regional infection trends and hospital-level results. With over 40 statistical tools available, this platform allows healthcare providers to compare individual test results with regional epidemiological data, facilitating better-informed treatment strategies. The comprehensive analysis provided by STAgora™ is critical for speeding up diagnoses and improving patient care.
Seegene's commitment to expanding access to both CURECA™ and STAgora™ is evident as the company aims to establish pilot partnerships with selected institutions by the end of the year. Early engagement was already seen at the ESCMID Global 2025 conference, signaling strong anticipation for these innovations.
According to Daniel Shin, Executive Vice President and Chief of Global Sales & Marketing at Seegene, "CURECA™ and STAgora™ are not just instruments or software; they signify a new benchmark that will reshape the landscape of diagnostics in clinical settings worldwide." Seegene's dedication to the development of diagnostic technologies spans more than 20 years, during which it has established its presence through significant contributions, such as providing over 340 million COVID-19 tests globally during the pandemic. This experience underscores the company’s capacity for innovation in the rapidly evolving field of molecular diagnostics.
While currently in a pre-commercialization stage, the technologies showcased at ADLM 2025 reflect the high potential for transforming workflows in clinical laboratories. CURECA™ and STAgora™ represent promising advancements that stand to improve diagnostics by reducing human error, enhancing efficiency, and better leveraging workforce capabilities. As Seegene prepares for broader commercialization, it is clear that the future of diagnostics is set for transformative change.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.